IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target raised by analysts at Stifel Nicolaus from $25.00 to $27.00. They now have a "buy" rating on the stock.
IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, revenue of $0.52M beats by $0.28M [Seeking Alpha]
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Medivir AB (OSTO:MVIR) Q3 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... [Yahoo! Finance]